Sort
15,273 grants matching “antimicrobial resistance”
Epicenters III: Translational Research to Prevent Healthcare Associated Infection
$1,000,000Richard Platt · Harvard Pilgrim Health Care, Inc. · U54 · FY2015 · CK
Rapid discovery of thousands of intact biosynthetic gene pathways for bioactive natural product compounds from un-sequenced filamentous fungi using a novel FAC-NGS tool
$1,000,000Chengcang Charles Wu · Intact Genomics, Inc. · R44 · FY2021 · AI
Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas
$1,000,000Christopher John Burns · Venatorx Pharmaceuticals, Inc. · R44 · FY2019 · AI
Commercialization Readiness Pilot (CRP) program support for: An Integrated Device for identification of bloodstream infections directly from blood
$1,000,000Alon Singer · Helixbind, Inc. · SB1 · FY2024 · AI
Narrow-spectrum Agents Acting against Helicobacter pylori
$1,000,000Kenneth Coleman · Arietis · R44 · FY2014 · AI
Development of a Dual-Targeting ClpP Activating Antibiotic
$1,000,000Michael Lafleur · Arietis · R44 · FY2023 · AI
Bioinformatics Tools and Services at NCBI for AMR Research
$1,000,000Carolyn Hill · Computercraft Corporation · N02 · FY2022 · LM
An Integrated Device for Rapid Bacteremia Diagnosis Direct from Whole Blood
$1,000,000Alon Singer · Helixbind, Inc. · R44 · FY2021 · AI
Development of Small Antimicrobial Peptide Mimics as Drug-Resistant and Susceptib
$1,000,000Richard W Scott · Fox Chase Chemical Diversity Center, Inc · R44 · FY2014 · AI
Massively Multiplexed dsDNA Invasion Arrays
$1,000,000Alon Singer · Helixbind, Inc. · R44 · FY2021 · AI
Lead optimization of oral DHFR inhibitor for the treatment of multidrug-resistant N. gonorrhoeae infections.
$1,000,000Ajit K Parhi · Taxis Pharmaceuticals, Inc. · R44 · FY2025 · AI
Nebulized ALX1 as a Treatment for Difficult Non-tuberculous Mycobacterial Lung Infections
$1,000,000Nathan Allan Stasko · Vast Therapeutics, Inc. · R44 · FY2025 · AI
Antibiotics for Recalcitrant Infection
$1,000,000Kenneth Coleman · Arietis · R44 · FY2017 · AI
An automated platform for direct-from-specimen identification of pathogens common in endocarditis
$1,000,000Alon Singer · Helixbind, Inc. · R44 · FY2019 · AI
Near patient molecular diagnostics test for infections
$1,000,000Vincent Jen-Jr Gau · Genefluidics, Inc. · SB1 · FY2017 · AI
Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
$1,000,000Nathan Allan Stasko · Vast Therapeutics, Inc. · R44 · FY2025 · AI
Random Shear Shuttle BAC Libraries for Antimicrobial Discovery from Soil Metageno
$1,000,000Chengcang Charles Wu · Lucigen Corporation · R44 · FY2012 · AI
HaloFilm: a spray-on, re-chargeable, re-applicable antimicrobial coating
$1,000,000Buket Demir · Halomine, Inc. · R44 · FY2023 · AI
Development of Small Antimicrobial Peptide Mimics as Drug-Resistant and Susceptib
$1,000,000Richard W Scott · Fox Chase Chemical Diversity Center, Inc · R44 · FY2013 · AI
PIPP Phase I: Advancing Environmental Surveillance for Pandemic Prediction in Remote and Resource Poor Settings
$1,000,000Scott Berry · University Of Kentucky Research Foundation · · FY2022 · CSE
Antibiotics for Recalcitrant Infection
$1,000,000Kenneth Coleman · Arietis · R44 · FY2015 · AI
Commercialization Readiness Pilot (CRP) program support for: An Integrated Device for identification of bloodstream infections directly from blood
$1,000,000Alon Singer · Helixbind, Inc. · SB1 · FY2022 · AI
Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis
$1,000,000Thomas Joseph Hannan · Fimbrion Therapeutics, Inc. · R44 · FY2022 · AI
An automated platform for direct-from-specimen identification of pathogens common in endocarditis
$1,000,000Alon Singer · Helixbind, Inc. · R44 · FY2021 · AI
Narrow-spectrum Agents Acting against Helicobacter pylori
$1,000,000Kenneth Coleman · Arietis · R44 · FY2015 · AI